Clinical course of inflammatory bowel disease and impact on liver disease outcomes in patients with autoimmune sclerosing cholangitis

Jeremy S Nayagam,Mandour O Mandour,Alison Taylor,Michael A Heneghan,Patrick CA Dubois,Bu Hayee, Huey Miin Lee,Babu Vadamalayan,Marianne Samyn,Deepak Joshi,Alexandra J Kent

Clinics and Research in Hepatology and Gastroenterology（2022）

引用 2|浏览3

暂无评分

摘要

•ASC-IBD frequently requires escalation of therapy to biologics or colectomy.•It is less common in ASC-IBD than in patients with IBD alone.•Patients taking second-line immunomodulators for ASC are at particular risk.•IBD does not impact on liver outcomes in ASC.•Multi-disciplinary management between gastroenterology and Hepatology is key.

查看译文

关键词

Primary sclerosing cholangitis,Colitis,Crohn's disease,Biologic

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要